urmjУральский медицинский журналUral Medical Journal2949-4389Ural State Medical University10.52420/umj.23.4.86NWTOOPurmj-1576Research ArticleОригинальные статьи | Original articlesOriginal articlesВлияние неоадъювантной химиотерапии на безрецидивную выживаемость при раке желудкаEffects of Neoadjuvant Chemotherapy on Reccurent Survival in Stomach CancerКрасильниковаН. Е.KrasilnikovaN. E.

Наталья Евгеньевна Красильникова — онколог

Екатеринбург

Natalya E. Krasilnikova — Clinical Oncologist

Ekaterinburg

Nkrasilnikova98@mail.ruКиселевЕ. А.KiselevE. A.

Евгений Александрович Киселев — кандидат медицинских наук, заместитель главного врача по лечебной работе

Екатеринбург

Evgenij A. Kiselev — Candidate of Sciences (Medicine), Deputy Chief Physician for Medical Work

Ekaterinburg

evgkiseliov@yandex.ruСвердловский областной онкологический диспансерРоссияSverdlovsk Regional Oncological CenterRussian Federation202403092024234Специальный выпуск «Онкология»86–93Copyright © Красильникова Н.Е., Киселев Е.А., 20242024Красильникова Н.Е., Киселев Е.А.Krasilnikova N.E., Kiselev E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.umjusmu.ru/jour/article/view/1576Введение

Введение. Комплексный подход — современный стандарт лечения рака желудка. При этом необходимо оценивать влияние смещения химиотерапии (ХТ) на предоперационный этап на отдаленные результаты лечения в реальной практике.

Цель работы — определить влияние неоадъювантной химиотерапии (НАХТ) на безрецидивную выживаемость пациентов (БРВ).

Материалы и методы

Материалы и методы. Проведено ретроспективное исследование 612 пациентов, получавших НАХТ в условиях Свердловского областного онкологического диспансера с января 2021 г. по декабрь 2023 г.

Результаты

Результаты. По результатам исследования выявлено, что НАХТ не влияет на общую выживаемость (ОВ) и БРВ в сравнении с адъювантной ХТ, не увеличивает риск послеоперационных осложнений и летальность. Полученные данные говорят о необходимости более тщательного отбора пациентов, которым необходима НАХТ, с учетом соматического статуса, сопутствующей патологии.

Обсуждение

Обсуждение. Определение зависимости между назначением НАХТ и благоприятным прогнозом после комбинированного лечения рака желудка имеет высокую прогностическую ценность.

Заключение

Заключение. На основании полученных данных можно утверждать, что НАХТ в составе периоперационной ХТ является стандартом лечения больных раком желудка II–III стадий. НАХТ не влияет на негативное течение послеоперационного периода.

Introduction

Introduction. Integrated approach — modern standard of treatment of stomach cancer. At the same time, it is necessary to assess the influence of chemotherapy on the pre-operative stage to the distant results of treatment in real practice.

The purpose of the study — determine the impact of neoadjuvant chemotherapy on patient survival.

Material and methods

Material and methods. A retrospective study of 612 patients receiving neoadjuvant chemotherapy in the conditions of Sverdlovsk Regional Oncological Center was conducted from January 2021 to December 2023.

Results and discussion

Results and discussion. The study found that neoadjuvant chemotherapy does not affect overall survival and diseasefree overall survival compared to adjuvant, does not increase the risk of postoperative complications and mortality. Findings suggest that more careful selection of patients is needed who require neoadjuvant chemotherapy, taking into account the somatic status associated with associated pathology.

Conclusion

Conclusion. Based on our findings, we can state that neoadjuvant chemotherapy as part of perioperative chemotherapy is the standard of patient treatment of gastric cancer II–III stage.

рак желудканеоадъювантная химиотерапиякомбинированное лечениеобщая выживаемостьобщая безрецидивная выживаемостьstomach cancerneoadjuvant chemotherapycombined treatmenttotal survivaltotal non-renewable survivalReferencesKaprin AD, Starinsky VV, Shakhzadova AO (eds.). The state of cancer care for the population of Russia in 2019. Moscow: P. A. Herzen Moscow State Medical Research Institute; 2020. 252 p.Kaprin AD, Starinsky VV, Shakhzadova AO (eds.). The state of cancer care for the population of Russia in 2019. Moscow: P. A. Herzen Moscow State Medical Research Institute; 2020. 252 p.Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, et al.; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): An international, open-label, randomised phase 3 trial. Lancet Oncol. 2018; 19(5):616–628. DOI: https://doi.org/10.1016/S1470-2045(18)30132-3.Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, et al.; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): An international, open-label, randomised phase 3 trial. Lancet Oncol. 2018; 19(5):616–628. DOI: https://doi.org/10.1016/S1470-2045(18)30132-3.Gantsev SK, Bochkova TV. Stomach cancer: A guide for doctors. Moscow: GEOTAR-Media; 2021.Gantsev SK, Bochkova TV. Stomach cancer: A guide for doctors. Moscow: GEOTAR-Media; 2021.Statistical Research and Applications Branch, National Cancer Institute. DevCan: Probability of developing or dying of cancer software. Version 6.7.8. Surveillance Research Program, Statistical Methodology and Applications, National Cancer Institute; 2020.Statistical Research and Applications Branch, National Cancer Institute. DevCan: Probability of developing or dying of cancer software. Version 6.7.8. Surveillance Research Program, Statistical Methodology and Applications, National Cancer Institute; 2020.GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1923–1994. DOI: https://doi.org/10.1016/S0140-6736(18)32225-6. Erratum in: Lancet. 2019; 393(10167):132. DOI: https://doi.org/10.1016/S0140-6736(18)33216-1. Erratum in: Lancet. 2019;393(10190): e44. DOI: https://doi.org/10.1016/S0140-6736(19)31429-1.GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1923–1994. DOI: https://doi.org/10.1016/S0140-6736(18)32225-6. Erratum in: Lancet. 2019; 393(10167):132. DOI: https://doi.org/10.1016/S0140-6736(18)33216-1. Erratum in: Lancet. 2019;393(10190): e44. DOI: https://doi.org/10.1016/S0140-6736(19)31429-1.Shakhzadova AO, Starinsky VV, Lisichnikova IV. Cancer care to the population of Russia in 2022. Siberian Journal of Oncology. 2023;22(5):5–13. (In Russ.). DOI: https://doi.org/10.21294/1814-4861-2023-22-5-5-13.Shakhzadova AO, Starinsky VV, Lisichnikova IV. Cancer care to the population of Russia in 2022. Siberian Journal of Oncology. 2023;22(5):5–13. (In Russ.). DOI: https://doi.org/10.21294/1814-4861-2023-22-5-5-13.Ajani JA, D’Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, et al. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(4):393–422. DOI: https://doi.org/10.6004/jnccn.2023.0019.Ajani JA, D’Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, et al. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(4):393–422. DOI: https://doi.org/10.6004/jnccn.2023.0019.Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma — 2nd English Edition. Gastric Cancer. 1998;1(1):10–24. DOI: https://doi.org/10.1007/PL00011681.Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma — 2nd English Edition. Gastric Cancer. 1998;1(1):10–24. DOI: https://doi.org/10.1007/PL00011681.Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251): 635–648. DOI: https://doi.org/10.1016/S0140-6736(20)31288-5.Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251): 635–648. DOI: https://doi.org/10.1016/S0140-6736(20)31288-5.López MJ, Carbajal J, Alfaro AL, Saravia LG, Zanabria D, Araujo JM, et al. Characteristics of gastric cancer around the world. Crit Rev Oncol Hematol. 2023;181:103841. DOI: https://doi.org/10.1016/j.critrevonc.2022.103841.López MJ, Carbajal J, Alfaro AL, Saravia LG, Zanabria D, Araujo JM, et al. Characteristics of gastric cancer around the world. Crit Rev Oncol Hematol. 2023;181:103841. DOI: https://doi.org/10.1016/j.critrevonc.2022.103841.Afanas’ev SG, Avgustinovich AV, Davydov IM, Volkov MIu. Neoadjuvant chemotherapy in the combined treatment of gastric cancer. P. A. Herzen Journal of Oncology. 2014;3(6):13–18. (In Russ.). DOI: https://doi.org/10.17116/oncolog2014613-18.Afanas’ev SG, Avgustinovich AV, Davydov IM, Volkov MIu. Neoadjuvant chemotherapy in the combined treatment of gastric cancer. P. A. Herzen Journal of Oncology. 2014;3(6):13–18. (In Russ.). DOI: https://doi.org/10.17116/oncolog2014613-18.Sedova MV, Batov MA, Kolomeytseva AA, Khomyakov VM, Volchenko NN, Fedenko AA. Total neoadjuvant chemotherapy according to the FOLFIRINOX regimen for locally advanced adenocarcinoma of the stomach and cardioesophageal junction: interim results. Research and Practical Medicine Journal. 2023; 10(3):8–20. (In Russ.). DOI: https://doi.org/10.17709//2410-1893-2023-10-3-1.Sedova MV, Batov MA, Kolomeytseva AA, Khomyakov VM, Volchenko NN, Fedenko AA. Total neoadjuvant chemotherapy according to the FOLFIRINOX regimen for locally advanced adenocarcinoma of the stomach and cardioesophageal junction: interim results. Research and Practical Medicine Journal. 2023; 10(3):8–20. (In Russ.). DOI: https://doi.org/10.17709//2410-1893-2023-10-3-1.Besova NS, Bolotina LV, Gamayunov SV, Kalinin AE, Kozlov NA, Malikhova OA, et al. Practical recommendations for the drug treatment of stomach cancer. Malignant tumors. 2022;12(3s2–1):382–400. (In Russ.). DOI: https://doi.org/10.18027/2224-5057-2022-12-3s2-382-400.Besova NS, Bolotina LV, Gamayunov SV, Kalinin AE, Kozlov NA, Malikhova OA, et al. Practical recommendations for the drug treatment of stomach cancer. Malignant tumors. 2022;12(3s2–1):382–400. (In Russ.). DOI: https://doi.org/10.18027/2224-5057-2022-12-3s2-382-400.Gorbunova VA, Stenina MB. Antitumor drug therapy. Moscow: GEOTAR-Media; 2022. 708 p.Gorbunova VA, Stenina MB. Antitumor drug therapy. Moscow: GEOTAR-Media; 2022. 708 p.World Health Organization (WHO). Global Health Estimates 2020: Deaths by cause, age, sex, by country and by region, 2000–2019. WHO; 2020.World Health Organization (WHO). Global Health Estimates 2020: Deaths by cause, age, sex, by country and by region, 2000–2019. WHO; 2020.Clinic and diagnosis of early gastric cancer. Moscow: Stiintsa; 2022. 124 p.Clinic and diagnosis of early gastric cancer. Moscow: Stiintsa; 2022. 124 p.Sukonko OG, Krasnyy SA (eds.). Algorithms of diagnosis and treatment of malignant tumors. Minsk; 2012. 506 p. (In Russ.).Sukonko OG, Krasnyy SA (eds.). Algorithms of diagnosis and treatment of malignant tumors. Minsk; 2012. 506 p. (In Russ.).Kuznetsova OA, Fedyanin MYu, Naidin GM, Besova NS, Tryakin AA. Drug therapy of metastatic gastric cancer. Malignant tumors. 2022;12(3s 1):17–26. (In Russ.).Kuznetsova OA, Fedyanin MYu, Naidin GM, Besova NS, Tryakin AA. Drug therapy of metastatic gastric cancer. Malignant tumors. 2022;12(3s 1):17–26. (In Russ.).Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. DOI: https://doi.org/10.3322/caac.21660.Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. DOI: https://doi.org/10.3322/caac.21660.Fukayama M, Rugge M, Washington MK. Tumours of the stomach. In: WHO Classification of Tumours. Lyon: IARC; 2019. P. 59–109.Fukayama M, Rugge M, Washington MK. Tumours of the stomach. In: WHO Classification of Tumours. Lyon: IARC; 2019. P. 59–109.Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al.; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–1957. DOI: https://doi.org/10.1016/s0140-6736(18)32557-1.Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al.; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–1957. DOI: https://doi.org/10.1016/s0140-6736(18)32557-1.Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–730. DOI: https://doi.org/10.1056/nejmoa010187.Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–730. DOI: https://doi.org/10.1056/nejmoa010187.Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D; ESMO Guidelines Committee. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38–v49. DOI: https://doi.org/10.1093/annonc/mdw350.Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D; ESMO Guidelines Committee. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38–v49. DOI: https://doi.org/10.1093/annonc/mdw350.Stilidi IS, Nered SN. Modern ideas about the basic principles of surgical treatment of locally advanced gastric cancer. Practical oncology. 2009;10(1):20–27. (In Russ.). EDN: https://elibrary.ru/pwiayp.Stilidi IS, Nered SN. Modern ideas about the basic principles of surgical treatment of locally advanced gastric cancer. Practical oncology. 2009;10(1):20–27. (In Russ.). EDN: https://elibrary.ru/pwiayp.Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D; ESMO Guidelines Committee. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38–v49. DOI: https://doi.org/10.1093/annonc/mdw350.Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D; ESMO Guidelines Committee. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38–v49. DOI: https://doi.org/10.1093/annonc/mdw350.Association of Oncologists of Russia; Russian Society of Clinical Oncology. Stomach cancer. Moscow: Ministry of Health of the Russian Federation. 83 p.Association of Oncologists of Russia; Russian Society of Clinical Oncology. Stomach cancer. Moscow: Ministry of Health of the Russian Federation. 83 p.

The authors declare that there are no conflicts of interest present.